Attio is powerful, highly configurable, real-time and beautifully designed, giving businesses the modern tool they need to grow and scale

SAN FRANCISCO and LONDON, March 2, 2023 — Attio, the company building the CRM of the future, today announced $23.5 million in Series A funding led by Redpoint Ventures, with continued participation from existing investors Balderton Capital and Point Nine. Attio has now secured $31.2 million from both American and European investors. The company will use the funding to accelerate engineering and product development and expand its go-to-market presence globally.

Attio is a radically new type of CRM that empowers companies to achieve what was, up until now, previously impossible for CRMs. With a powerful data model built on cutting-edge, modern architecture, Attio makes it possible for companies to rapidly build a real-time CRM that fits their business’ unique workflows and data structures. This is in contrast to legacy CRMs, which, although offer robust data models, have outdated user experiences, rely on manual data input, and are slow to deploy and configure.

“Attio’s mission is to build a CRM that is not only beautiful and intuitive, but powerful enough to empower businesses to scale. That’s why we’ve spent the last three years building a powerful architecture from scratch specifically for CRM,” said Nicolas Sharp, co-founder, and CEO of Attio. “We’ve seen challenger CRMs come to the market repeatedly with the same proposition: a more straightforward CRM. However, focusing on that alone won’t cut it unless you also build a robust data model to help businesses evolve and scale.”

Attio is now generally available after being in public beta for three months and private beta for just over a year. It has over 2,000 customers in over 100 countries around the world. Current customers include OpenAI, Causal, Pallet, Dopt, On Deck, and Coca-Cola.

Bringing CRM into the Modern Era

CRM is one of the most widely-used B2B technologies in the world. However, it continues to frustrate users because the entire ecosystem is built on archaic architectures that were designed 20 years ago when the speed, scale, and capabilities that businesses require today could not be conceptualized.

As a result, even though legacy CRMs can have incredibly powerful data models, users cannot take full advantage of them due to their slow and complex nature. The most advanced deployments can take years to carry out and the user experiences are clunky and out-of-date.

“Legacy CRM has impressive architectures, but they have an inherent weakness in their foundation. No matter how much they upgrade or rebuild, they remain constrained by the legacy decisions and technology they started with decades ago,” said Alexander Christie, co-founder and CTO of Attio. “With billions of lines of code and over a hundred thousand customers, you cannot move fast to execute on new technologies or customer needs, even with data model rebuilds. That is the reality of scale.”

Meanwhile, no-code CRM solutions on the market today focus on delivering a nicer user experience, but it comes at the expense of the power and functionality companies need to truly scale. Users are essentially stuck between two options: extremely slow, complicated legacy CRMs with a powerful data model or fast, basic CRMs with a simple and rigid data model.

Attio solves this issue by providing a modern CRM with a robust data model that is also completely customizable, fast, intuitive, and easy to use.

Attio: Flexible and Customizable From Day 1 to IPO

Attio is powerful, real-time, multiplayer, and beautifully designed without sacrificing any of the necessary features businesses need to grow and scale.

“Attio is building from the ground up a modern CRM with a composable UX, an extensible data model, and advanced workflows and integrations. It balances ease-of-use with underlying data sophistication to scale with businesses from day 1 to IPO,” said Alex Bard, managing director at Redpoint Ventures and former Salesforce executive. “Legacy CRMs are complex to set up, generally rely on manual input, and are designed primarily to store data, rather than provide insights and intelligence. Attio can be set up nearly instantly and delivers immediate impact to users through intelligent insights and actions. That’s why they call it Customer Relationship Magic.”

Immediately when using the product for the first time, Attio syncs with a business’ email and calendar systems to create a full global view of every relationship a business has. This automatically includes complete detailed profiles, with a timeline of interactions and conversations, intelligence on the strength of each relationship and enriched with hundreds of extra data points. Attio also allows for easy integration of data from other sources through developer-friendly APIs and first-party integrations.

Teams can then sort and filter millions of customer records in milliseconds. Users have the freedom to use that data to build highly customizable workflows for virtually any industry or scenario – pulling from a library of templates or using a blank canvas to start from scratch. The flexibility of Attio’s data model and architecture means users can adapt and change it rapidly on the fly for any use case, seamlessly scaling with a company as it grows.

“Attio is unlike any CRM we’ve ever encountered. It’s flexible, customizable and truly multiplayer,” said Alon Bartur, co-founder and CEO of early-stage startup Dopt, an Attio customer. “It has played a crucial role in helping us build and scale our go-to-market engine. From tackling sales pipelines to customer success, onboarding and everything in between, it constantly evolves with us as our business grows and has become an indispensable part of our technology stack.”

“From the moment we first learned about Attio, we knew right away that it had massive potential to transform how we manage customer relationships,” said Daniel Waterhouse, general partner at Balderton Capital. “It’s been incredible to see how much the product has evolved since our last investment. Attio’s combination of an amazing UX and powerful data architecture is something truly unique in the market. We believe in their team and vision to build the future of CRM.”

“With Attio, teams can leverage the flexibility and customization of a no-code tool while still getting all the power and features you’d expect from a CRM with a potent data structure to organize your relationships,” said Ricardo Sequerra, partner at Point Nine. “We’re incredibly impressed with the product’s rapid evolution and are excited to see Attio become generally available and work towards their vision of reinventing CRM.”

Availability

Attio is now generally available. To get started, go to https://attio.com.

About Attio

Attio is the CRM of the future. Real-time, completely customizable and intuitively collaborative, Attio’s powerful data model and next-generation architecture allows businesses of all sizes and at all stages to rapidly build the exact CRM they need. To learn what Attio can do for you, visit https://attio.com.

Logo: https://mma.prnewswire.com/media/2013990/Attio_Logo.jpg

SOURCE ATTIO LIMITED

Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals

BOSTON, March 2, 2023 — The co-founder of Aldevron, Dr. John Ballantyne, has invested $3M in CureLab Oncology and CureLab Veterinary. The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr. Ballantyne served there as chief scientific officer. The investment positions both companies to attain the R&D milestones needed to secure additional rounds of funding.

Both CureLab Oncology and CureLab Veterinary are developing therapies that employ plasmids (circular DNA encoding a gene called p62/SQSTM1). CureLab Oncology is applying the p62 plasmid to treat human cancers. Following impressive clinical data presented at the European Society for Medical Oncology Congress in Paris, and the considerable ongoing progress of the company’s clinical studies, the funds will enable CureLab Oncology to ramp up toward FDA-monitored clinical trials for triple-negative breast cancer and platinum-resistant ovarian cancer in 2023.

“I have been observing the CureLab journey since Aldevron produced the very first batch of their product. I have witnessed the CureLab team growing and evolving, obtaining patent protection around the world, and keeping an eye on their pre-clinical and clinical progress. The team and the strength of their recent clinical data is what made me want to invest,” said Dr. John Ballantyne.

“Distributing Dr. Ballantyne’s investment among the two companies will greatly reduce the R&D risks for both CureLab Oncology and CureLab Veterinary,” said Dr. Alexander Shneider, CEO of CureLab Oncology.

The research activities of the two CureLab sister companies are highly synergistic. The data obtained in real-life veterinary settings, in pets, serves as a much stronger predictor for human clinical trials than experiments conducted on laboratory animals. For example, if CureLab Veterinary demonstrates that the product is effective in the treatment of canine osteoarthritis or inflammatory bowel syndrome, both of which are highly prevalent among dogs, CureLab Oncology could extend its clinical programs to treat these pathologies.

For the treatment of domestic animals, CureLab Veterinary received positive clinical results in 10 out of 11 dogs diagnosed with breast cancer. The company is looking to take its patented p62 plasmid technology through the USDA-CVB process with a view to marketing new anti-cancer and anti-inflammatory technologies for use by veterinarians.  

“As an industry leader in both thought and action, I am pleased that John has decided to support our efforts to bring innovative animal technology through the US approval process,” said Robert Devlin, president of CureLab Veterinary. “Through his generous support, we hope to help many animals and bring joy to pet owners worldwide.”

CureLab Veterinary is currently engaged in a crowdfunding effort with Netcapital.

About Elenagen

CureLab’s lead investigational compound is code-named Elenagen, an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In animal studies and Phase I/II human trials conducted ex-US, Elenagen demonstrated promise in reversing tumor grade, changing the tumor microenvironment, and enhancing the anti-cancer effects of chemotherapy. Experimental results also indicate mitigation of chronic inflammation and stimulation of an immune response to the tumor.

About CureLab Veterinary

Today, our four-legged family members are living longer than ever. Unfortunately, with this longer lifespan, our furry friends now are experiencing many of the same cancers and diseases due to chronic inflammation as their pet parents. CureLab Veterinary, a sister company of CureLab Oncology, is dedicated to bringing advanced therapies to treat cancer and inflammatory diseases to support better pet health and longevity. To learn more, visit curelabveterinary.com.

About CureLab Oncology

CureLab Oncology Inc. is a pre-IPO, clinical-stage immuno-oncology biotech company headquartered in the greater Boston area, Massachusetts. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelab.com.

Media contact:
Tim Cox, ZingPR, [email protected]

SOURCE CureLab Oncology Inc.

DURHAM, N.C., March 1, 2023 — InsightFinder, the leading predictive observability platform provider, rounded out a successful 2022 with a $10M Series A fundraising round and numerous product innovations for 2022. The fundraising round was led by Silicon Valley venture capital, and also included support from Yu Galaxy, Acadia Woods Partners, Eight Roads Ventures, Eastlink Capital, Fellows Fund, IDEA Fund Partners, and Triangle Tweener Fund.

InsightFinder obtained SOC2 compliant certification, taking a large step towards entertaining large brands at scale on the platform. In addition, InsightFinder has recently been listed on Datadog’s marketplace and as an Amazon certified partner. Both partnerships represent the highest standards of SaaS customer solutions, illustrating the critical value-add of InsightFinder’s incident prediction capabilities. The company has achieved over 200% subscription renewal from all of its customers for its award-winning incident prediction solution.

InsightFinder focused on several areas of innovation in 2022 including federated learning, cloud cost efficiency for Azure, AWS, GCP, predictive capacity planning and more. These advancements will enable customers to optimize their cloud application performance while reducing costs in ways previously unavailable or difficult to determine. .

InsightFinder is committed to delivering superior customer experience through its innovative products. With the newly raised funds and its upcoming product releases, InsightFinder is well positioned to continue its growth trajectory in 2023.

About InsightFinder:

DevSecOps, IT operations, and site reliability engineering (SRE) teams rely on InsightFinder to predict and prevent outages in complex distributed architectures. Powered by unique patented capabilities for incident prediction, unsupervised active learning and auto-remediation, the InsightFinder platform continuously learns from machine data to identify and fix problems before they impact web or application performance. Customers including Credit Suisse, Dell and Visa gain value quickly starting with an InsightFinders free trial and the company’s pre-built integrations with Datadog, New Relic, PagerDuty and other popular DevSecOps partners. Learn more at insightfinder.com 

InsightFinder.com | @InsightFinders | [email protected]

SOURCE InsightFinder

FREDERICK, Md., March 1, 2023 — Today, Theradaptive, a leading biotechnology company specializing in therapeutic delivery platforms, announces a Technology & Therapeutic Development Award (TTDA) of $4 million from the U.S. Department of Defense (DOD) awarded through the Peer Reviewed Medical Research Program (PRMRP) of the Congressionally Directed Medical Research Programs (CDMRP). The contract will fund its OsteoAdapt regenerative therapeutic product for spine and trauma repair to first in human clinical studies.

Theradaptive’s OsteoAdapt product was granted three breakthrough medical device designations by the U.S. Food and Drug Administration (FDA) in 2021 and 2022 for various spinal indications. OsteoAdapt is created by combining AMP2 protein, a novel bone regenerative biologic, with ReBOSSIS, a 510K-approved implant material. OsteoAdapt has the capability to precisely direct bone regrowth where it is needed in the body.

The funds from the DOD contract will enable Theradaptive to continue its work to meet regulatory requirements and scale up Good Manufacturing Practices-compliant manufacturing of the OsteoAdapt product in preparation for clinical studies. After a request for an Investigational Device Exemption (IDE) is submitted to the FDA for approval, Theradaptive will initiate human clinical trials.

Theradaptive’s OsteoAdapt, powered by their proprietary AMP2 biologic, has beaten the standard of care in all preclinical studies to date. The DOD funding will enable the development of OsteoAdapt and the promise of life-changing surgery for Service Members and civilians with degenerative or traumatic spinal, extremity, craniomaxillofacial, and dental injuries.  37% of adults over the age of 30 and over 80% of adults over the age of 50 have at least one degenerated vertebral disc.

CEO and founder of Theradaptive, Dr. Luis Alvarez, Ph.D., believes the funding is a major step towards clinical trials: “This award affirms Theradaptive’s rapid and successful execution of earlier stage programs funded by Department of Defense, and provides funding crucial to advance a new kind of therapeutic that upon FDA approval will address massive unmet needs among Service Members, Veterans, and in the general population.”

“We understand the challenges that many service members face, particularly when traumatic extremity injuries progress to limb amputation or when years of physical activity lead to spinal degeneration, disc injury, and pain. The support provided by this contract will accelerate the completion of product development milestones that will allow Theradaptive to reach clinical trials faster and get us one step closer to providing this game-changing therapy to patients who need it most.”

Dr. Leon J. Nesti, a surgeon at the Walter Reed National Military Medical Center offers additional perspective: “Starting from early inspiration from Luis’s military career, Theradaptive has made significant progress in developing a regenerative technology that has now been demonstrated for orthopedic repair. Their technology offers a transformative approach to address medical challenges through regenerative mechanisms that stimulate stem cells, including the potential to restore patients’ quality of life by accelerating the process of bone regeneration. This technology is one of the few that addresses the stem cell niche directly by delivering growth factors to those stem cells. This work will have a large scientific impact and will benefit Service Members and Veterans.”

About Theradaptive

Founded in 2016 and headquartered in Maryland, U.S., Theradaptive is a venture-backed biopharmaceutical company with the goal of leveraging their therapeutic delivery platform that can deliver biologics where they are needed in the body with high precision and persistence to address unmet medical needs. Theradaptive is led by CEO Luis Alvarez, Ph.D., and its innovative platform has started to enable new therapeutics in spine, orthopedic and soft tissue repair as well as targeted immuno-oncology.

This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Congressionally Directed Medical Research Programs under Award No. (W81XWH-22-1-0875) for an amount of $3,979,465.00. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

Contact:
Serena Lertora
[email protected]

SOURCE Theradaptive

New funding will enable Shef to help thousands more local cooks turn their
culinary talents into a small business

SAN FRANCISCO, March 1, 2023 — Shef, the nation’s leading chef-to-consumer marketplace, today announced plans to expand nationwide after closing a $73.5 million Series B funding round last year, bringing the company’s total funding to date to more than $100 million. The largest investment ever in a chef-to-consumer marketplace, the funding will help Shef connect talented local cooks anywhere in the United States with customers looking for healthy, high-quality food options prepared by members of their community.

Shef’s previously closed Series B round was led by CRV, with participation from Andreessen Horowitz and Amex Ventures. The round included $7M in venture debt. Other investors include celebrity chefs Andrew Zimmern (Bizarre Foods), Carla Hall (The Chew, Top Chef), Kristen Kish (Top Chef, Iron Chef) and Nyesha Arrington (Next Level Chef); athletes Russell Westbrook, Odell Beckham Jr. and Candace Parker; comedians Jimmy O. Yang and Lilly Singh; entrepreneur and best-selling author Tony Robbins; Visa CFO Vasant Prabhu; AngelList founder Naval Ravikant; Poshmark founder Manish Chandra; and former Airbnb executives Belinda Johnson and Joe Zadeh. They join a long list of existing investors including Katy Perry, Orlando Bloom, Aarón Sánchez, Andre Iguodala, and Alexis Ohanian.

Shef launched in the Bay Area in 2019 and currently operates in 11 states plus Washington, D.C., reaching 70 million people. Since its launch four years ago, thousands of local, food safety certified “shefs” – 85% of whom are women and 80% people of color – have joined the marketplace. Many are immigrants or refugees, representing nearly 100 countries around the world. Cooks on Shef have earned tens of millions of dollars of net income to support themselves and their families.

“Finding Shef has changed my life here,” said Shef Adriana, a Nicaraguan refugee who was forced to flee her beloved home country and successful Managua restaurant four years ago. “My dream is to open a restaurant again someday. Until then, Shef enables me to share my cherished family recipes with customers and earn much-needed income. It makes me so happy to give my customers a taste of where I come from, hopefully reminding them of their own mother’s or grandmother’s cooking too.”

The new funding will enable Shef to help thousands more local cooks turn their culinary talents into a small business for the first time, while meeting the needs of busy consumers looking for healthy, high-quality meal options. As of 2022, all 50 states now allow for the sale of certain types of homemade food, with many states clarifying laws to embrace and regulate the practice. Starting today, talented cooks anywhere across the country can apply to sell their homemade specialties on Shef. Shef will also be investing in key product developments, including new preference and customization features that will deliver a uniquely personalized experience.

“With our plans to bring Shef nationwide this year, we’re focused on enabling anyone, anywhere to become a food entrepreneur – something that would have been a true economic lifeline for both Alvin’s and my family when they immigrated to the U.S.,” said Shef co-founder and CEO Joey Grassia. “Demand for Shef has grown dramatically over the past four years – both from those interested in cooking on the platform to earn much-needed income, as well as consumers looking for more affordable, healthy ways to feed their families. We’re thrilled to be able to meet this demand and fill a significant gap in the market between home cooking and takeout.”

“Shef is not only incubating the next generation of American food entrepreneurs and future restaurant owners, they’re unlocking an entirely new category of how we feed our families,” said Saar Gur, general partner at CRV. “Neighbors feeding neighbors is already a widely accepted tradition around the world. Now talented local cooks can simultaneously pursue their passion while also providing their families with another meaningful source of income by providing homemade dishes to those nearby, something that’s even more relevant given the tough economy. We’re proud to support a company that puts the interests of shefs front and center while meeting a huge consumer demand for more healthy, high-quality food options in their community.”

“At American Express, we’re all about shopping small and supporting the next generation of small business owners,” said Kevin Tsang, Managing Director for Consumer Services Investments at Amex Ventures. “Shef has turned starting a small food business – something previously cost-prohibitive for most – into a reality for thousands of people across the country. In supporting Shef, we’re honored to invest in a majority female and people of color marketplace that’s dramatically lowering the price of entry into the food industry.”

Beyond supporting the fast-growing community of shefs across the country, Shef is also committed to giving back – both to non-profits and causes in places where Shef operates, as well as around the world. Shef and its customers have donated more than 10,000 meals to those in need. Shef also established an initiative to help Afghan refugees in the wake of the 2021 crisis, expediting the applications of any Afghan refugee interested in cooking on Shef and setting aside $3,500 per person to help pay for training, supplies, and marketing support.

About Shef

Shef is a chef-to-consumer marketplace that enables talented local cooks to connect directly with customers in their community and earn a meaningful income selling authentic, homemade dishes. Shef was founded by Joey Grassia and Alvin Salehi, both sons of immigrants whose parents struggled to make ends meet after arriving in the U.S. The “she” in Shef is in honor of their mothers who worked incredibly hard to support and nourish their families and communities. Shef is their way of bringing a community-based food system to life, where anyone can gain access to a meaningful income and take care of their neighbors, one meal at a time. The service is currently available in several markets across the United States, including San Francisco, New York, New Jersey, Seattle, Chicago, Houston, Austin, Boston, Los Angeles, Washington, D.C., Maryland, Virginia, and Atlanta, with plans to expand nationwide this year. To order food from a local cook in your area, or for more information on how to become a shef, visit www.shef.com.

Contact:
Amy Dudley, Head of Communications, Shef
[email protected]
203-470-5881

SOURCE Shef

• The round was led by Diagram Ventures with participation from Fenbushi Capital, Sfermion, Big Brain Holdings, Builder Capital and Sparkle Ventures (strategic venture arm supported by Animoca Brands and The Sandbox)
• Helika’s $4 million seed funding round will enable the company to expand its operations and develop its platform to better serve the Web3 community

TORONTO, March 1, 2023 – Helika, a Web3 gaming and NFT analytics platform, has announced the successful close of its $4 million seed funding round to scale product and marketing analytics for Web3. The funding round was led by Diagram Ventures, with participation from Sfermion, Sparkle Ventures, Big Brain Holdings, Fenbushi, and Builder Capital.

“We’re confident with our investment in Helika as they’ve shown impressive customer traction within NFT communities and with large game studios in a short amount of time,” said Ken Nguyen, Head of Crypto at Diagram Ventures. “We see Helika at the forefront of a rapidly evolving industry, and believe its innovative technology and forward-thinking approach position the company for significant growth in the years to come.”

Most companies in Web3 struggle to make data-driven decisions to drive growth. Helika’s no-code platform with integrated in-game, on-chain and social media analytics allows companies to understand their user’s behavior and interactions to increase engagement, retention, user acquisition, and make better strategic decisions. The platform offers a suite of powerful products allowing Helika clients such as Yuga Labs and Treasure to gather sales and royalty data, analyze user wallet activity, onboard new users, and determine optimal mint pricing for future NFT drops.

“We are thrilled to have the support of such a strong group of investors as we continue to build out our platform and expand our data sources,” said Anton Umnov, Founder and CEO of Helika. “This funding round will enable us to grow our team, improve our product, connect more sources of data from other blockchains, and continue to gather insights to share with the Web3 community.”

The lack of visibility on reach, retention, and revenue of NFT collections has been a major challenge for many web3 gaming studios and popular NFT projects.  Helika’s platform provides these insights so that top web3 companies can make informed, strategic decisions.

Helika’s $4 million seed funding round will enable the company to expand its operations and develop its platform to better serve the Web3 community.

About Helika

Helika is a web3 technology platform that delivers real-time analytics and onboards new users to gaming studios and popular NFT collections. With a focus on integrated analytics from Web2, in-game, on-chain and social media data, Helika helps top Web3 brands such as Yuga labs and Treasure to understand their communities, increase user acquisition and engagement, and drive overall growth with a data-driven approach.

Helika is backed by top VC firms including Diagram Ventures, Sfermion, Sparkle Ventures, Big Brain Holdings, Fenbushi and Builder Capital.

For more information, visit helika.io

SOURCE Helika

BOSTON, March 1, 2023 — Chloris Geospatial, a technology company that measures natural capital from space, closes seed extension round of funding led by AXA IM Alts and Orbia Ventures, with participation from existing investors At One Ventures and Counteract.

Companies are challenged with adopting nature-based solutions with increasing speed, scale, and integrity to meet climate and biodiversity goals. Chloris developed technology that uses satellite data to reliably assess forest carbon dynamics, including forest growth and degradation.

Marco Albani, CEO of Chloris Geospatial, commented, “We are excited to welcome AXA IM Alts and Orbia as new investors. The market needs robust and reliable natural capital insights to deploy high-integrity nature-based solutions. We will use the new funding to advance sensor-fusion technology and equip customers with globally consistent estimates for 2000-2022. This aligns with corporate sustainability reporting frameworks and allows us to assess the impact of forest projects in the voluntary carbon markets. The funding will also extend spatial coverage and grow customer support services.”

Jonathan Dean, Head of Impact Investing at AXA IM Alts, commented, “AXA IM Alts is committed to investing in companies and projects to preserve our planet’s natural ecosystems and address climate risk. Chloris’s innovative solutions will enhance the credibility of natural capital projects and associated ecosystem services claims and provide the necessary assurance to support continued investments in natural capital. This aligns with our ambition to create scalable solutions that contribute to global protection, restoration, and sustainable management of natural capital globally.”

Shai Albaranes, VP Innovation, and Ventures at Orbia commented, “We are delighted to be part of this round of funding in Chloris Geospatial. Climatech is a key focus area for Orbia Ventures, with this investment forming part of a wider strategy to implement our commitment to advancing life around the world by developing and investing in products and services that mitigate the impact of climate change and move us closer to our goal of being carbon neutral while helping decarbonize the planet.”

About Chloris Geospatial

Chloris Geospatial is a provider of science-based forest carbon insights built with Earth observation data and machine learning. The Chloris Platform enables high-integrity nature-based solutions to climate change. For more information, visit www.chloris.earth.

SOURCE Chloris Geospatial

TEL AVIV, Israel, March 1, 2023 — Hexa, a 3D asset visualization and management platform, announced it has raised a $20.5 Million Series A round from Point72 Ventures, Samurai Incubate, Sarona Partners, and HTC. Hexa’s proprietary tech stack digitizes products like furniture and fashion using existing 2D images and AI, creating a new 3D model, a digital twin of the physical object. This digital twin can then be deployed on websites, social media and in AR applications. The models are interactive, too. Consumers control the model with their cursor, allowing them to inspect the asset from any angle. Hexa provides storage, management, distribution, and analysis of the models its customers create.

Hexa believes the Internet will increasingly become 3D. These 3D spaces in the Metaverse need to be populated with dimensional objects, furnishings, displays, merchandise. Users can do more than simply look at things, they can navigate around them. Product pages will increasingly use 3D representations, replacing traditional 2D pictures and thumbnails. Hexa’s 3D tools guide brands and retailers as they create, manage, distribute, and analyze 3D projects.

“We are convinced 3D content will be at the heart of all online and offline retail,” says Hexa CEO and co-founder Yehiel Atias. “You have to make it easy to use, inexpensive, and fast to return on your investment.” Old methods of creating assets through photogrammetry or lidar scanning are less accurate and more expensive.

Amazon, Macy’s, Logitech, Unity and Crate & Barrel are among the dozens of companies that now use the Hexa 3D platform for making, managing and deploying their 3D assets. The models can be moved onto any web page, social media site, or game engine with a snippet of code. Hexa’s 3D Viewer facilitates parallel processing, loading at the maximum frames per second without sacrificing computational power. 3D models load as quickly as 2D images and are immediately interactive.

“Taking a product library, converting it to 3D, inspecting it and deploying it is a tremendous undertaking,” said co-founder and CTO Jonathan Clark. “But we’ve eliminated the pain points with a fast, scalable solution to a very specific problem everyone selling anything in the Metaverse is going to encounter.”

Having raised $1.2 million in pre-seed funding and $5.5 million in seed funding rounds, Hexa’s total funding to date stands at $27.2 million. With a team of 100 global employees working in engineering and business development, the company aims to utilize the new funding to support further expansion. 

About Hexa
Founded in 2018, Hexa is an industry leader focused on its mission to build the world’s most powerful 3D tech stack, supporting the many use cases of synthetic data. Hexa’s technology enables businesses to create, manage, distribute, and analyze high-fidelity 3D models, 360-degree viewing, and AR experiences at scale. For more information or to get in touch with Hexa, visit https://www.hexa3d.io/.

Media Contacts:
Shira Zwebner/Leigh Brandt
Lightspeed PR & Marketing for Hexa 
[email protected]
[email protected]

SOURCE Hexa

PALM BEACH, Fla., March 1, 2023 — Newly rebranded Viper Equity Partners, now Viper Partners, has launched a new division offering equipment, expansion and acquisition loans to doctors and medical business owners nationwide. As the MSO and DSO markets continue to enjoy massive growth, Viper recognizes that many doctors are not ready to sell. A newly launched program offers loans up to $10M with fast approvals and very competitive rates. Leading this new division is industry veteran, Karen E. Vickers. “I am so excited about this opportunity and agree with Viper on the necessity for “Top Shelf” representation for doctors looking for financial help.” Viper, true to form, has strong relationships with leading lenders, including JP Morgan Chase, and a goal of matching clients with programs that make sense (offering preapprovals in 72 hours in most cases).

Viper gets the business and understands doctors’ needs. Viper Founder, David C. Branch, saw the hole in their business model. “We have helped thousands of doctors with transitions and sale deals but not everyone is ready for an exit due to their age or specific goals. We want to help them now with their growth plans and then be there for them when it is time to exit.”

Viper will represent all doctors and provide assistance whether they need simple equipment loans, full expansion financing, buildouts, acquisitions or loan refinancing. Viper has a strong reputation among lenders which enables them to secure loan packages with better rates than brokers or doctors can get on their own.

Also new is Viper’s national roll out of a premier real estate division focused on selling medical commercial buildings. Armed with a national contract with Coldwell Banker, Viper launched this division in January and already has 17 properties under contract. Again, Viper responded to the demand from their clients to help them sell their buildings. Partners at Viper have over 30 years experience in this market, which is a huge benefit to doctors across all specialties. “It is so important in real estate to have true representation and knowledge. Exceptional deals are very available and we have the name and reputation that doctors trust,” stated David C. Branch.

Viper understands the medical business from both sides of the table. Their strong suit is bringing growth-minded practice owners to private equity and financing partners, and now with the launch of the Loan and Real Estate divisions, they continue to dominate all things medical and bring superior support to medical professionals.

Viper Partners is a leading investment banking firm. For more information contact Karen E. Vickers at [email protected] or (561)-951-1822

SOURCE Viper Partners